Clinical Trials Logo

Carcinoma, Hepatocellular clinical trials

View clinical trials related to Carcinoma, Hepatocellular.

Filter by:
  • Approved for marketing  
  • Page 1

NCT ID: NCT05345678 Approved for marketing - Clinical trials for Unresectable Hepatocellular Carcinoma

Himalaya Early Access Program

Start date: n/a
Phase:
Study type: Expanded Access

To provide early access (i.e., before marketing authorisation) to tremelimumab 300 mg IV administered once on Day 1 of Cycle 1 plus durvalumab 1500 mg IV followed by durvalumab 1500 mg IV Q4W monotherapy in patients with unresectable HCC.

NCT ID: NCT02436044 Approved for marketing - Clinical trials for Hepatocellular Carcinoma

HAIC Using Oxaliplatin Plus Fluorouracil/Leucovorin for Patients With Locally Advanced HCC

Start date: n/a
Phase:
Study type: Expanded Access

A large proportion of Asian patients with HCC present with locally advanced or metastatic disease,at which point they are ineligible for curative treatments.Oxaliplatin plus fluorouracil/leucovorin intravenous infusion was proved effective in prolonging progression-free survival(PFS) than doxorubicin as palliative chemotherapy in patients with advanced HCC from Asia. Besides, hepatic arterial infusion chemotherapy (HAIC)is a widely used method for primary or metastasis liver tumor with high local tumor response. To our knowledge, there have not been any prospective studies to assess the safety and effecacy of HAIC using oxaliplatin plus fluorouracil/leucovorin for patients with locally advanced HCC.Thus,the purpose of this phase 2 study was to assess the safety and effecacy of HAIC using oxaliplatin plus fluorouracil/leucovorin for patients with locally advanced HCC.

NCT ID: NCT01076517 Approved for marketing - Liver Cancer Clinical Trials

A Humanitarian Device Exemption Treatment Protocol of TheraSphere For Treatment of Unresectable Hepatocellular Carcinoma

Start date: n/a
Phase:
Study type: Expanded Access

To provide Therasphere treatment for patients diagnosed with unresectable liver cancer.

NCT ID: NCT00906984 Approved for marketing - Clinical trials for Hepatocellular Carcinoma

TheraSphere® for Treatment of Unresectable Hepatocellular Carcinoma

TheraSphere
Start date: n/a
Phase:
Study type: Expanded Access

The purpose of this protocol is to provide TheraSphere treatment for patients with liver cancer who cannot be treated by surgery. The effect on the tumor and any side effects of TheraSphere treatment will be examined. This study will provide supervised and limited access to TheraSphere treatment at University California Irvine Medical Center. TheraSphere is a medical device containing yttrium-90 (Y-90), a radioactive material that has been used previously in the treatment of liver tumors. When Y-90 is incorporated into very tiny glass beads (TheraSphere), it can be injected to the liver through blood vessels supplying the liver. This allows a large dose of radiation to be delivered to the tumor with less risk of toxic effects from radiation to other parts of the body or to healthy liver tissue. The radiation from TheraSphere is contained within the body and becomes minimally active within 7 days after treatment due to physical decay. The glass beads remain in the body, but do not cause any health problems. TheraSphere has been approved for use in the treatment of liver cancer in the United States by the Food and Drug Administration on a limited basis.